Management of hepatitis C virus infection in hemodialysis patients

Area of Science:

• Nephrology
• Infectious Diseases
• Hepatology

Background:

• Hepatitis C virus (HCV) infection is more prevalent in patients undergoing maintenance hemodialysis (MHD) compared to the general population.
• Chronic HCV infection negatively impacts quality of life, life expectancy, and increases mortality risk in MHD patients, including renal transplant rejection.
• Recent HCV transmissions in MHD settings are primarily linked to inadequate universal precautions, despite erythropoietin use for anemia management.

Purpose of the Study:

• To review the current landscape of HCV infection in MHD patients.
• To highlight the importance of stringent universal precautions in preventing HCV transmission.
• To discuss current and future treatment strategies for HCV in MHD patients.

Main Methods:

• Review of literature on HCV prevalence, transmission, and treatment in MHD patients.
• Analysis of the impact of universal precautions on HCV infection rates.
• Evaluation of current and emerging therapeutic approaches for HCV in this population.

Main Results:

• Strict adherence to universal precautions has significantly reduced new HCV infections in many hemodialysis units.
• Physicians must remain vigilant for anti-HCV negative HCV infection and occult HCV infections in MHD patients.
• Standard and pegylated interferon alpha monotherapies at reduced doses are current mainstays, but optimizing sustained virological response and minimizing side effects remain challenges.

Conclusions:

• While universal precautions are effective, ongoing vigilance for subtle HCV infections is necessary in MHD patients.
• Current interferon-based therapies have limitations, necessitating research into more effective and safer treatments.
• IFNα-free regimens using direct-acting antivirals represent a promising future direction for HCV treatment in MHD patients, requiring further investigation.